News about Clinical Trials

AskBio's Viralgen to Supply Commercial Drug for Parkinson's Phase 2 Trial

AskBio’s Viralgen will supply commercial-scale drug product for the REGENERATE-PD Phase II trial of ametefgene parvec (AB-1005), leveraging next-generation manufacturing to deliver high-purity gene therapy for Parkinson’s disease.

Clinical Trials | 22/04/2026 | By News Bureau |  102

AstraZeneca's Tozorakimab Hits Key Phase 3 Goal in COPD Trial

AstraZeneca reports positive Phase III MIRANDA trial results for tozorakimab in COPD, marking its third successful pivotal study and reinforcing the potential of its IL-33-targeting biologic to transform respiratory care.

Clinical Trials | 21/04/2026 | By News Bureau |  122

NHS Speeds Up Clinical Trials, Accelerating Patient Access to New Treatments

The Government-backed reforms and Euro 137 million investment cut trial set-up times, strengthening the UK’s position as a global leader in clinical research and innovation.

Clinical Trials | 17/04/2026 | By News Bureau |  117

GlycoNex Secures PMDA Nod for First-in-Human Trial of Cancer Drug GNX1021

Japan’s Pharmaceuticals and Medical Devices Agency approves Phase I clinical trial of GlycoNex’s novel antibody-drug conjugate targeting gastrointestinal cancers.

Clinical Trials | 16/04/2026 | By News Bureau |  228

Samsung Bioepis Starts Phase 1 Trial for Nectin-4 ADC SBE303

Samsung Bioepis launches Phase 1 trial of SBE303, a Nectin-4 targeting ADC, marking a key step in advancing its oncology pipeline and Antibody-Drug Conjugate development.

Clinical Trials | 16/04/2026 | By News Bureau |  100

GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers

GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.

Clinical Trials | 14/04/2026 | By News Bureau |  139

Hoth Therapeutics Reports Positive HT-VA CRADA Data

Hoth Therapeutics reports positive HT-VA data showing GDNF improves liver fat metabolism, reduces fat production and may outperform semaglutide in MAFLD and obesity.

Clinical Trials | 14/04/2026 | By News Bureau |  196

Allogene Reports ALPHA3 Data: Cema-Cel Shows 58 Percent MRD Clearance in LBCL

Allogene reports ALPHA3 interim data showing 58 percent MRD clearance with cema-cel in LBCL, rapid ctDNA reduction and favourable safety profile with no serious adverse events.

Clinical Trials | 14/04/2026 | By News Bureau |  116

MetaVia Advances Obesity Drug Development with First Patient Dosed in DA-1726 Phase I Trial

MetaVia initiates Part 3 of its phase I trial for DA-1726, evaluating higher-dose strategies to enhance weight loss, metabolic outcomes and tolerability in obesity and cardiometabolic disease treatment.

Clinical Trials | 13/04/2026 | By News Bureau |  107

Sparian Biosciences Begins Phase I Trial of Oral Pain Drug SBS-147 Targeting Opioid Alternatives

Sparian Biosciences advances SBS-147 into Phase I trials, aiming to develop a safer, non-opioid oral treatment for acute and chronic pain.

Clinical Trials | 11/04/2026 | By News Bureau |  168